OBSV
Price:
$0.1018
Market Cap:
$11.00M
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an ...[Read more]
Industry
Biotechnology
IPO Date
2018-07-13
Stock Exchange
NASDAQ
Ticker
OBSV
According to ObsEva SA’s latest financial reports and current stock price. The company's current ROE is 551.93%. This represents a change of -0.37% compared to the average of 553.98% of the last 4 quarters.
The mean historical ROE of ObsEva SA over the last ten years is -242.59%. The current 551.93% ROE has changed -327.51% with respect to the historical average. Over the past ten years (40 quarters), OBSV's ROE was at its highest in in the June 2022 quarter at 1.56%. The ROE was at its lowest in in the December 2020 quarter at -222.06%.
Average
-242.59%
Median
-180.52%
Minimum
-993.13%
Maximum
-30.72%
Discovering the peaks and valleys of ObsEva SA ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 346.90%
Maximum Annual ROE = -30.72%
Minimum Annual Increase = -85.64%
Minimum Annual ROE = -993.13%
Year | ROE | Change |
---|---|---|
2022 | -352.22% | 95.12% |
2021 | -180.52% | -81.82% |
2020 | -993.13% | 346.90% |
2019 | -222.22% | 325.57% |
2018 | -52.22% | -4.30% |
2017 | -54.57% | -34.88% |
2016 | -83.80% | 172.80% |
2015 | -30.72% | -85.64% |
The current ROE of ObsEva SA (OBSV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-508.62%
5-year avg
-360.06%
10-year avg
-242.59%
ObsEva SA’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ObsEva SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ObsEva SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is ObsEva SA's ROE?
How is the ROE calculated for ObsEva SA (OBSV)?
What is the highest ROE for ObsEva SA (OBSV)?
What is the 3-year average ROE for ObsEva SA (OBSV)?
What is the 5-year average ROE for ObsEva SA (OBSV)?
How does the current ROE for ObsEva SA (OBSV) compare to its historical average?